O	0	1	A
O	2	12	randomized
O	13	16	and
O	17	21	open
O	21	22	-
O	22	27	label
O	28	33	phase
O	34	36	II
O	37	42	trial
O	43	50	reports
O	51	54	the
O	55	63	efficacy
O	64	66	of
B-intervention	67	78	neoadjuvant
I-intervention	79	89	lobaplatin
O	90	92	in
O	93	99	breast
O	100	106	cancer
O	106	107	.

O	108	117	Currently
O	117	118	,
O	119	122	one
O	123	128	sixth
O	129	131	of
O	132	138	triple
O	138	139	-
O	139	147	negative
O	148	154	breast
O	155	161	cancer
O	162	163	(
O	163	167	TNBC
O	167	168	)
O	169	177	patients
O	178	181	who
O	182	189	receive
O	190	199	docetaxel
O	200	201	(
O	201	202	T
O	202	203	)
O	204	207	and
O	208	218	epirubicin
O	219	220	(
O	220	221	E
O	221	222	)
O	223	225	as
O	226	237	neoadjuvant
O	238	250	chemotherapy
O	251	258	achieve
O	259	260	a
O	261	271	pathologic
O	272	280	complete
O	281	289	response
O	290	291	(
O	291	294	pCR
O	294	295	)
O	295	296	.

O	297	301	This
O	302	307	study
O	308	317	evaluates
O	318	321	the
O	322	328	impact
O	329	331	of
O	332	338	adding
O	339	349	lobaplatin
O	350	351	(
O	351	352	L
O	352	353	)
O	354	356	to
O	357	360	the
O	361	363	TE
O	364	371	regimen
O	371	372	.

O	373	377	Here
O	377	378	,
O	379	381	we
O	382	386	show
O	387	391	data
O	392	396	from
B-total-participants	397	400	125
O	401	409	patients
O	410	411	(
B-control-participants	411	413	63
B-control	414	416	TE
O	417	420	and
B-intervention-participants	421	423	62
O	424	427	TEL
O	428	436	patients
O	436	437	)
O	437	438	.

O	439	443	Four
O	444	452	patients
O	453	456	did
O	457	460	not
O	461	469	complete
O	470	473	all
O	474	477	the
O	478	484	cycles
O	484	485	.

O	486	489	Two
O	489	490	-
O	490	495	sided
O	496	497	P
O	498	504	values
O	505	509	show
O	510	514	that
O	515	518	the
O	519	527	addition
O	528	530	of
O	531	532	L
O	533	534	(
B-iv-bin-percent	534	536	38
I-iv-bin-percent	536	537	.
I-iv-bin-percent	537	538	7
I-iv-bin-percent	538	539	%
O	540	542	vs
O	542	543	.
B-cv-bin-percent	544	546	12
I-cv-bin-percent	546	547	.
I-cv-bin-percent	547	548	7
I-cv-bin-percent	548	549	%
O	549	550	,
O	551	552	P
O	553	554	=
O	555	556	0
O	556	557	.
O	557	560	001
O	560	561	)
O	562	575	significantly
O	576	585	increases
O	586	589	the
B-outcome	590	594	rate
I-outcome	595	597	of
I-outcome	598	601	pCR
I-outcome	602	604	in
I-outcome	605	608	the
I-outcome	609	615	breast
I-outcome	616	619	and
I-outcome	620	623	the
I-outcome	624	630	axilla
O	631	632	(
O	632	636	TpCR
O	636	637	)
O	638	641	and
O	642	645	the
B-outcome	646	653	overall
I-outcome	654	662	response
I-outcome	663	667	rate
O	668	669	(
O	669	672	ORR
O	672	673	;
B-iv-bin-percent	674	676	93
I-iv-bin-percent	676	677	.
I-iv-bin-percent	677	678	5
I-iv-bin-percent	678	679	%
O	680	682	vs
O	682	683	.
B-cv-bin-percent	684	686	73
I-cv-bin-percent	686	687	.
I-cv-bin-percent	687	688	0
I-cv-bin-percent	688	689	%
O	689	690	,
O	691	692	P
O	693	694	=
O	695	696	0
O	696	697	.
O	697	700	003
O	700	701	)
O	701	702	.

O	703	706	The
O	707	717	occurrence
O	718	720	of
B-outcome	721	726	grade
I-outcome	727	728	3
I-outcome	728	729	-
I-outcome	729	730	4
I-outcome	731	737	anemia
O	738	741	and
B-outcome	742	758	thrombocytopenia
O	759	761	is
O	762	768	higher
O	769	771	in
O	772	775	the
O	776	779	TEL
O	780	785	group
O	786	787	(
B-iv-bin-percent	787	789	52
I-iv-bin-percent	789	790	.
I-iv-bin-percent	790	791	5
I-iv-bin-percent	791	792	%
O	793	795	vs
O	795	796	.
B-cv-bin-percent	797	799	10
I-cv-bin-percent	799	800	.
I-cv-bin-percent	800	801	0
I-cv-bin-percent	801	802	%
O	803	806	and
B-iv-bin-percent	807	809	34
I-iv-bin-percent	809	810	.
I-iv-bin-percent	810	811	4
I-iv-bin-percent	811	812	%
O	813	815	vs
O	815	816	.
B-cv-bin-percent	817	818	1
I-cv-bin-percent	818	819	.
I-cv-bin-percent	819	820	7
I-cv-bin-percent	820	821	%
O	822	834	respectively
O	834	835	)
O	835	836	.

O	837	842	These
O	843	850	results
O	851	862	demonstrate
O	863	867	that
O	868	871	the
O	872	880	addition
O	881	883	of
O	884	885	L
O	886	888	to
O	889	892	the
O	893	895	TE
O	896	903	regimen
O	904	906	as
O	907	918	neoadjuvant
O	919	931	chemotherapy
O	932	940	improves
O	941	944	the
O	945	949	TpCR
O	950	953	and
O	954	957	the
O	958	961	ORR
O	962	967	rates
O	968	970	of
O	971	975	TNBC
O	976	979	but
O	980	984	with
O	985	994	increased
O	995	999	side
O	1000	1007	effects
O	1007	1008	.
